Ardent Health (NYSE:ARDT – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.
ARDT has been the subject of several other research reports. Guggenheim upped their target price on Ardent Health from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $13.00 price objective on shares of Ardent Health in a research note on Thursday, August 6th. Weiss Ratings downgraded Ardent Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Royal Bank Of Canada lifted their price objective on Ardent Health from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Monday, August 10th. Finally, Truist Financial boosted their target price on Ardent Health from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $13.05.
Ardent Health Price Performance
Ardent Health (NYSE:ARDT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.06). Ardent Health had a net margin of 1.22% and a return on equity of 10.35%. The company had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.59 billion. Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. On average, analysts predict that Ardent Health will post 0.96 EPS for the current fiscal year.
Institutional Investors Weigh In On Ardent Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Ardent Health by 103.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company’s stock valued at $194,000 after buying an additional 7,182 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Ardent Health by 1,684.9% in the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock valued at $10,558,000 after acquiring an additional 724,841 shares during the period. Jane Street Group LLC increased its position in shares of Ardent Health by 235.1% in the first quarter. Jane Street Group LLC now owns 57,468 shares of the company’s stock valued at $790,000 after acquiring an additional 40,318 shares during the period. Acadian Asset Management LLC raised its stake in shares of Ardent Health by 574.9% during the first quarter. Acadian Asset Management LLC now owns 40,238 shares of the company’s stock valued at $550,000 after acquiring an additional 34,276 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Ardent Health by 0.6% during the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock valued at $3,918,000 after acquiring an additional 1,769 shares during the last quarter.
About Ardent Health
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Read More
- Five stocks we like better than Ardent Health
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
